Tumor-targeted p53-gene therapy enhances the efficacy of conventional chemo/radiotherapy

Journal of Controlled Release

Volumn 74, Issue 1-3, 2001, Pages 115-128

  Xu, L ^a   Pirollo, K F ^a   Chang, E H ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

Gene therapy; Liposomes; p53; Targeting

Indexed keywords

ANTINEOPLASTIC AGENT; BETA GALACTOSIDASE; FOLIC ACID; IMMUNOLIPOSOME; PROTEIN P53; TRANSFERRIN; TRANSFERRIN RECEPTOR;

APOPTOSIS; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DNA DAMAGE; DRUG EFFICACY; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HEAD AND NECK CARCINOMA; HUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; REGULATORY MECHANISM; TUMOR RESISTANCE; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; GENE TARGETING; GENE THERAPY; GENES, P53; HUMANS; LIPOSOMES; RADIOPHARMACEUTICALS;

EID: 0035816146     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(01)00324-8     Document Type: Conference Paper

References (55)

1. Non-viral gene delivery for p53
2. Clinical implications of the p53 gene
3. P53 and response to chemotherapy and radiotherapy
4. The p53 gene as a modifier of intrinsic radiosensitivity: Implications for radiotherapy
5. Cox-2, iNOS and p53 as play-makers of tumor angiogenesis
6. Targeted p53 gene therapy mediated radiosensitization and chemosensitization
7. Lipofection, a highly efficient, lipid mediated DNA-transfection procedure
8. Introduction
9. Cationic lipid binding to DNA: Characterization of complex formation
10. Progress in gene delivery research and development
11. Cationic lipid-mediated gene transfer: Current concepts
12. The perplexing delivery mechanism of lipoplexes
13. Effective treatment of early endobronchial cancer with regional administration of liposome-p53
14. 33PDNA following intravenous administration of DNA-cationic lipid complexes in mice: Use of a novel radionuclide approach
15. Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice
16. Systemic gene therapy with p53 inhibits breast cancer: Recent advances and therapeutic implications
17. Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity
18. Gene therapy with p53 and a fragment of thrombospondin I inhibits human breast cancer in vivo
19. Ligand-polycation conjugates for receptor-targeted gene transfer
20. Strategies to accomplish gene therapy via the receptor-mediated endocytosis pathways
21. Receptor ligand-facilitated gene transfer: Enhancement of liposome-mediated gene transfer and expression by transferrin
22. Folate-targeted, anionic liposome-entrapped polylysine-condensed DNA for tumor cell-specific gene transfer
23. Folate receptors
24. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis
25. Tumor-selective radiopharmaceutical targeting via receptor-mediated endocytosis of gallium-67-deferoxamine-folate
26. Systematic p53 gene therapy in combination with radiation results in human tumor regression
27. Folate receptor of human mammary adenocarcinoma
28. Elevated transferrin receptor content in human prostate cancer cell lines assessed in vitro and in vivo
29. Breast carcinoma and the role of iron metabolism a cytochemical, tissue culture, and ultrastructural study
30. Transferrin receptor in oral tumors
31. The transferrin receptor: Its diagnostic value and its potential as therapeutic target
32. Cloning and expression of a chimeric antibody directed against the human transferrin receptor
33. Receptor blockade with monoclonal antibodies as anti-cancer therapy
34. Pedroso de Lima, Cationic liposomes as gene transfer vectors: Barriers to successful application in gene therapy
35. Transferrin-liposome-mediated p53 sensitization of squamous cell carcinoma of the head and neck radiation in vitro
36. Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts
37. Antibody-targeted stealth liposomes
38. Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies
39. Use of targeted cationic liposomes in enhanced DNA delivery to cancer cells
40. Anti-HER2 immunoliposomes for targeted drug delivery
41. Anti-HER2 immunoliposomes for targeted therapy of human tumors
42. Selective transfer of a lipophilic prodrug of 5-fluorodeoxyuridine from immunoliposomes to colon cancer cells
43. Delivery of c-myb antisense oligodeoxynucleotides to human neuroblastoma cells via disialoganglioside GD(2)-targeted immunoliposomes: Antitumor effects
44. GD2-mediated melanoma cell targeting and cytotoxicity of liposome-entrapped fenretinide
45. Stealth liposomes: From steric stabilization to targeting
46. Stabilization of cationic liposome-plasmid DNA complexes by polyamines and poly(ethylene glycol)-phospholipid conjugates for efficient in vivo gene delivery
47. Stabilized plasmid-lipid particles: Construction and characterization
48. Stabilized plasmid-lipid particles: Factors influencing plasmid entrapment and transfection properties
49. Targeted gene delivery by ligand-PEG post-coating stabilized lipoplex and polyplex. 3rd Annual Meeting of the American Society of Gene Therapy, Denver, CO, May 31-June 4, 2000
50. Structure of DNA-cationic liposome complexes: DNA intercalation in multilamellar membranes in distinct interhelical packing
51. Improved DNA: Liposome complexes for increased systemic delivery and gene expression
52. Preparation of liposomes
53. Mechanism of stealth liposome accumulation in some pathological tissues